NCT02376010View on ClinicalTrials.gov

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 2, 2015

Primary Completion Date

April 1, 2018

Study Completion Date

April 1, 2018

Conditions
Atherosclerosis
Interventions
DRUG

rivaroxaban

DRUG

Warfarin

Trial Locations (1)

90502

Los Angeles Biomedical Research Institute, Torrance

All Listed Sponsors
lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT02376010 - Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium | Biotech Hunter | Biotech Hunter